- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00787267
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC (TOP0801)
Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
On this study patients will receive dasatinib, a targeted therapy, for advanced NSCLC that has progressed after previous therapy. Safety and response to dasatinib will be assessed.
Fresh frozen tumor tissue must be available for genomics analysis prior to initiating dasatinib therapy. A biopsy must be obtained after any prior chemotherapy. If fresh frozen tumor tissue is not available, a biopsy will be required to participate in this trial.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Lung cancer is the leading cause of cancer death in the United States. Twenty to seventy-five percent of patients initially treated with surgery or radiotherapy recur and become candidates for systemic therapy. Src expression has been identified in a majority of NSCLC cell lines and may be important in hypoxic growth and angiogenesis of NSCLC.
This phase II trial will investigate the activity of the oral Src inhibitor dasatinib in advanced stage NSCLC. We hypothesize that the inhibition of Src pathway with dasatinib will show anti-tumor activity in advanced NSCLC, with a tolerable safety profile.
Fresh frozen tissue is needed for the genomics analysis, thus a biopsy will be required to participate in this trial. The genomic analysis will determine if the tumor is Src-active or Src-inactive and responses to dasatinib compared. In stage I, 40 patients will be treated without prior knowledge of their tumoral Src-activity. If all stage I responses are observed in the Src-active patients, the second stage will only accrue that cohort. If all responses are observed in the Src-inactive cohort, the activity of dasatinib and genomic determination of dasatinib response will be re-evaluated. Otherwise, if during Stage I, responses are observed in both cohorts, they will be accrued separately and evaluated in a two-stage manner.
Dasatinib will be give orally twice daily and continue until progression of disease, intolerable toxicity or patient withdrawal. Imaging studies will be done pre-treatment then every 6 weeks to assess radiologic response to therapy.
Patients will be followed for 30 days after the last dose of dasatinib to assess toxicity.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke University Medical Center
-
Durham, North Carolina, Vereinigte Staaten, 27705
- Durham VA Medical Center
-
Raleigh, North Carolina, Vereinigte Staaten, 27609
- Duke Raleigh
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Histological/cytological documented non-small cell lung cancer (NSCLC). Documentation of recurrence required if treated with surgical resection and/or external beam radiation therapy (XRT) with curative intent and now have recurrent disease.
- Fresh tissue biopsy material for genomics analysis prior to initiating dasatinib. If prior XRT, tissue biopsy must be outside XRT field. Biopsy must be after any prior chemotherapy.
Prior treatment (tx) to include one of the following:
- At least 1 prior systemic regimen (IV or oral agent) for Stage IV NSCLC or for recurrent disease.
- Recurrence within 12 months after completion of systemic neoadjuvant/adjuvant chemotherapy for early stage NSCLC.
- Combined modality platinum-based tx for Stage III NSCLC.
- Prior XRT permitted if ≥1 week since completion, XRT must be <25% of bone marrow reserve.
- At least one, non-radiated, measurable lesion (per RECIST).
- Age ≥18 years.
- Eastern Cooperative Oncology Group (ECOG) 0-2.
Adequate Organ Function:
- Total bilirubin < Upper limit normal (ULN)
- Hepatic enzymes (AST, ALT) ≤2.5x ULN
- Serum creatinine <1.5x ULN
- Hemoglobin ≥9 gm/dL
- Neutrophil count (ANC/AGC) ≥1500 per μL
- Platelets ≥100,000 per μL
- Prothrombin time (PT)/a Partial thromboplastin time (PTT) ≤1.5x control
- No other serious medical or psychiatric illness.
- Ability to take oral medication (dasatinib must be swallowed whole).
- Women of childbearing potential must have negative serum pregnancy test ≤72 hours and not >7 days prior to starting study drug.
- Sexually active males and females of reproductive potential must agree to use adequate method of contraception during tx and for at least 4 weeks after study drug stopped.
- Signed, written informed consent including Health Insurance Portability and Accountability Act (HIPAA) according to institutional guidelines.
Exclusion Criteria:
- Previous or concomitant malignancy in past 2 years other than curatively treated carcinoma in situ of cervix, or basal cell/squamous cell carcinoma of the skin.
- Prior tx with dasatinib or other agents that inhibit Src.
- Evidence of symptomatic pleural effusions (grade 2) unless undergo therapeutic thoracentesis as part of non-study care. Successful pleurodesis allowed. Patients who require supplemental oxygen or with oxygen saturation on room air <89% are not eligible. Pericardial effusions of any grade are not eligible.
- Untreated documented symptomatic central nervous system (CNS) metastases.
Cardiac Symptoms:
- Uncontrolled angina, congestive heart failure(CHF)or myocardial infarction within 6 months
- Diagnosed congenital long QT syndrome
- Any h/o clinically significant ventricular arrhythmias
- Prolonged QT corrected (QTc) interval on pre-entry EKG (>450 msec)
- Uncontrolled B/P as defined as >160/90 on B/P therapy
- Hypokalemia or hypomagnesaemia if it cannot be corrected.
- H/o diagnosed congenital acquired bleeding disorders.
- Ongoing or recent (≤3 months) significant (≥grade 3) GI bleeding.
Con Meds:
- Drugs having risk of causing Torsades de Pointes (must stop drug 7 days before dasatinib);
- Current therapeutic dose unfractionated heparin, low-molecular weight heparin, or coumadin therapy;
- St. John's Wort must be stopped while on dasatinib;
- IV bisphosphonates stopped 2 weeks pre/6 weeks post dasatinib.
- Prisoners/subjects compulsorily detained for tx of psychiatric and/or physical illness.
- Pregnant or breastfeeding.
- Active or uncontrolled infection requiring IV antibiotics.
- Impairment of GI function/disease that may alter absorption of dasatinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
- Received investigational drugs ≤4 weeks prior to starting study drug and/or not recovered from side effects of such therapy. Any other anti-neoplastic and/or molecular therapy must be discontinued 7 days prior to starting dasatinib.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Dasatinib
After a biopsy is done to obtain fresh frozen tumor tissue (Stage I), dasatinib is to be administered as an oral dose of 70 mg twice daily on a continuous basis for 6 weeks. Every 6 weeks radiologic exam will be done to assess response. Treatment will continue until progression of disease, intolerable toxicity or patient withdrawal. For Stage II, a biopsy to obtain fresh frozen tumor tissue will also be done. Depending on results from Stage I and results of biopsy, treatment with dasatinib will be determined. |
70 mg PO twice daily until progression.
Re-assess radiographically every 6 weeks.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Tumor Response
Zeitfenster: 2 years
|
Tumor response rate was defined by RECIST criteria: CR (complete response) = disappearance of all target lesions taking as reference the baseline sum of the longest diameter (LD); PR (partial response) = at least a 30% decrease in the sum of the longest diameter of target lesions; PD (progressive disease) = at least a 20% increase in the sum of the longest diameter of target lesions as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; SD (stable disease) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since the treatment started |
2 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Overall Survival
Zeitfenster: Progression and survival every 6 months
|
Overall survival (OS) is the duration from date of consent to date of death from any cause.
|
Progression and survival every 6 months
|
Grade 3-5 Toxicity Associated With Dasatinib Treatment
Zeitfenster: Duration of dasatinib treatment plus 30 days
|
Number of subjects with Grade 3-5 toxicity as assessed using NCI CTCAE criteria with the attribution of possibly, probably, or definitely related to protocol treatment.
|
Duration of dasatinib treatment plus 30 days
|
Describe Change in Serum Levels of C-terminal Cross-linked Collagen I Between Pre-treatment and 6 Weeks After Starting Dasatinib.
Zeitfenster: 2 years
|
2 years
|
|
Determine Relationship Between K-ras Gene Mutation and Response to Dasatinib.
Zeitfenster: 2 years
|
2 years
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Michael Kelley, MD, Duke University
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen der Atemwege
- Neubildungen
- Lungenkrankheit
- Neubildungen nach Standort
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Lungentumoren
- Karzinom, nicht-kleinzellige Lunge
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Proteinkinase-Inhibitoren
- Dasatinib
Andere Studien-ID-Nummern
- Pro00008303
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Nicht-kleinzelligem Lungenkrebs
-
National Cancer Institute (NCI)AbgeschlossenAIDS-bedingtes peripheres/systemisches Lymphom | AIDS-assoziiertes diffuses großzelliges Lymphom | AIDS-bedingtes diffuses gemischtzelliges Lymphom | AIDS-bedingtes kleines Noncleaved-Cell-LymphomVereinigte Staaten
-
National Cancer Institute (NCI)AbgeschlossenAIDS-bedingtes peripheres/systemisches Lymphom | AIDS-assoziiertes diffuses großzelliges Lymphom | AIDS-bedingtes immunoblastisches großzelliges Lymphom | AIDS-bedingtes kleines Noncleaved-Cell-LymphomVereinigte Staaten
-
Jason Robert GotlibNovartis; Novartis PharmaceuticalsAbgeschlossenSystemische Mastozytose, aggressiv (ASM) | Leukämie, Mastzelle | Hämatologische Non-Mast Cell Lineage Disease (AHNMD)Vereinigte Staaten
-
Adelphi Values LLCBlueprint Medicines CorporationAbgeschlossenMastzellleukämie (MCL) | Aggressive systemische Mastozytose (ASM) | SM w Assoc Clonal Hema Non-Mast Cell Lineage Disease (SM-AHNMD) | Schwelende systemische Mastozytose (SSM) | Indolente systemische Mastozytose (ISM) ISM-Untergruppe vollständig rekrutiertVereinigte Staaten
-
Children's Oncology GroupNational Cancer Institute (NCI)AbgeschlossenDiffuses großzelliges Lymphom im Kindesalter | Immunoblastisches großzelliges Lymphom im Kindesalter | Burkitt-Lymphom im Kindesalter | Unbehandelte akute lymphoblastische Leukämie im Kindesalter | Stadium I des großzelligen Lymphoms im Kindesalter | Stadium I des kleinen, nicht gespaltenen... und andere BedingungenVereinigte Staaten
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.RekrutierungDiffuses großzelliges B-Zell-Lymphom | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | Refraktäres diffuses großzelliges B-Zell-Lymphom | Primäres mediastinales (thymisches) großes B-Zell-Lymphom | Follikuläres Lymphom Grad 3b | Transformierte follikuläre Lymphe zu Diff Large B-Zell-Lymphom und andere BedingungenVereinigte Staaten
-
Mitchell CairoRekrutierungHodgkin-Lymphom | Sichelzellenanämie | Akute Leukämie | Beta-Thalassämie | Non-Hodgkin-Lymphom | Schwere aplastische Anämie | Diamond-Blackfan-Anämie | Amegakaryozytäre Thrombozytopenie | KostmannVereinigte Staaten
-
National Cancer Institute (NCI)BeendetLymphoproliferative Störung nach der Transplantation | Rezidivierendes großzelliges Lymphom im Kindesalter | Rezidivierendes kindliches lymphoblastisches Lymphom | Rezidivierendes kleinzelliges Lymphom im Kindesalter | Rezidivierendes/refraktäres Hodgkin-Lymphom im Kindesalter | AIDS-bedingtes... und andere BedingungenVereinigte Staaten
-
National Cancer Institute (NCI)Aktiv, nicht rekrutierendWeichteilsarkom | Osteosarkom | Ewing-Sarkom | Bösartiges Gliom | Ependymom | Rhabdoider Tumor | Fortgeschrittenes bösartiges solides Neoplasma | Refraktärer bösartiger fester Neoplasma | Rhabdomyosarkom | Rezidivierende bösartige solide Neubildung | Rezidivierendes Neuroblastom | Refraktäres Neuroblastom | Refraktäres... und andere BedingungenVereinigte Staaten, Puerto Rico
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLCAbgeschlossenAIDS-bedingtes peripheres/systemisches Lymphom | AIDS-assoziiertes diffuses großzelliges Lymphom | AIDS-bedingtes diffuses gemischtzelliges Lymphom | AIDS-bedingtes diffuses kleinzelliges Lymphom | AIDS-bedingtes immunoblastisches großzelliges Lymphom | AIDS-assoziiertes lymphoblastisches... und andere BedingungenZimbabwe, Kenia
Klinische Studien zur Dasatinib
-
Bristol-Myers SquibbAbgeschlossenPharmakokinetische Studie an gesunden TeilnehmernVereinigte Staaten
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Abgeschlossen
-
Hyoung Jin KangNoch keine RekrutierungAkute lymphoblastische Leukämie, Pädiatrie
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedAbgeschlossen
-
National Cancer Institute (NCI)ZurückgezogenNeoplasma hämatopoetischer und lymphoider Zellen | Fortgeschrittenes Lymphom | Fortgeschrittenes bösartiges solides Neoplasma | Refraktäres Lymphom | Refraktärer bösartiger fester Neoplasma | Refraktäres Plasmazell-MyelomVereinigte Staaten
-
National Cancer Institute (NCI)NRG OncologyBeendetRezidivierendes Eileiterkarzinom | Rezidivierendes Ovarialkarzinom | Rezidivierendes primäres Peritonealkarzinom | Klarzelliges Zystadenokarzinom der Eierstöcke | Klarzelliges Adenokarzinom des Endometriums | Wiederkehrender UteruskorpuskrebsVereinigte Staaten
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers SquibbAbgeschlossen
-
Norwegian University of Science and TechnologyAbgeschlossenLeukämie, myeloische, chronische PhaseSchweden, Finnland, Norwegen
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, nicht rekrutierendChronische myeloische Leukämie in der chronischen Phase, BCR-ABL1-positiv | Philadelphia-Chromosom-positiv, BCR-ABL1-positiv, chronische myeloische LeukämieVereinigte Staaten
-
Gruppo Italiano Malattie EMatologiche dell'AdultoAktiv, nicht rekrutierendChronisch-myeloischer LeukämieItalien